Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015399 | 1.00 | ALDH1A1 (0.31) | ALDH1A1HPGDALPLNPC1MAPT | |
| SCHEMBL30397150 | 1.00 | ALDH1A1 (0.31) | ALDH1A1HPGDALPLNPC1MAPT | |
| SCHEMBL30396858 | 0.96 | ALPL (0.34) | ALPLNPC1MAPTHTTRAB9A | |
| SCHEMBL29015360 | 0.96 | ALPL (0.34) | ALPLNPC1MAPTHTTRAB9A | |
| SCHEMBL24189621 | 0.96 | ALPL (0.34) | ALPLNPC1MAPTHTTRAB9A | |
| SCHEMBL31342394 | 0.89 | MAPT (0.33) | HPGDALPLMAPT | |
| SCHEMBL25764619 | 0.88 | SMN1; SMN2 (0.34) | ALDH1A1HPGDNPC1MAPTHTT | |
| SCHEMBL18989880 | 0.85 | CA12 (0.36) | HPGDNPC1MAPTHTTRAB9A | |
| SCHEMBL18989878 | 0.85 | CA12 (0.36) | HPGDNPC1MAPTHTTRAB9A | |
| SCHEMBL30310480 | 0.85 | CA12 (0.36) | HPGDNPC1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2039/4885HPGD 4005/4885ALPL 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.